0
Sickle Cell Care Expansion Act of 2023
12/15/2023, 3:57 PM
Summary of Bill HR 3100
Key provisions of the bill include:
1. Establishing a national sickle cell disease registry to track the prevalence of the disease and improve data collection for research purposes. 2. Increasing funding for sickle cell research, including studies on new treatment options and potential cures. 3. Improving access to quality care for individuals with sickle cell disease, including increased availability of specialized healthcare providers and treatment centers. 4. Enhancing education and awareness efforts to promote early detection and intervention for individuals at risk of sickle cell disease. Overall, the Sickle Cell Care Expansion Act of 2023 aims to address the challenges faced by individuals with sickle cell disease and improve their quality of life through better access to care and support services. The bill has received bipartisan support in Congress and is seen as a positive step towards improving outcomes for those affected by this chronic condition.
Congressional Summary of HR 3100
Sickle Cell Care Expansion Act of 2023
This bill establishes programs to increase treatment and other services for populations with sickle cell disease. Sickle cell disease is an inherited blood disorder that can lead to pain, anemia, infections, and stroke.
Specifically, the Department of Health and Human Services (HHS) must award grants to federally qualified health centers, community-based organizations, or other nonprofits that treat or otherwise support populations with sickle cell disease for education and advocacy programs concerning the disease. HHS must also award grants to nonprofits, including hospitals or institutions of higher education, that provide comprehensive care to populations with sickle cell disease for programs to support the transition from pediatric to adult care for patients with the disease.
Additionally, the Health Resources and Services Administration must establish a program to provide scholarships or student loan repayment awards to individuals who commit to engage in clinical practice or research related to sickle cell disease for a period of obligated service as physicians.
